Here is a number that should concern anyone on a GLP-1 medication: fewer than one in four patients are still taking their medication after one year. That figure comes from UT Southwestern research led by Dr. Jaime Almandoz, and it means roughly 75 percent of people who start Ozempic, Wegovy, Mounjaro, or Zepbound eventually stop — usually because of cost, insurance loss, side effects, or supply issues.
What happens next is where the real problem starts. Most people who stop regain weight. That part is well understood. What is less well understood — and what an NPR investigation published April 15, 2026 explored in detail — is what happens to muscle during these stop-start cycles. The answer is not good.
How Much Muscle Are You Actually Losing?
Up to 40 percent of all weight lost on GLP-1 medications is lean muscle mass, not fat. That finding comes from Texas Tech medical chemist Mahmoud Salama Ahmed, and it is significantly higher than the muscle loss seen with behavioral diets alone, where the ratio is typically 20 to 25 percent muscle.
To put that in concrete terms: if you lose 30 pounds on Wegovy, approximately 12 pounds of that may be muscle. If you then stop the medication and regain 25 pounds — which studies show happens in 60 to 70 percent of patients within a year of stopping — that regained weight is almost entirely fat. Your body does not rebuild muscle at the same rate it stores fat.
The net result after one stop-restart cycle: you weigh roughly the same as before, but your body composition is worse. You have less muscle and more fat than when you started. This is the pattern that metabolic researchers are now calling the "GLP-1 cycling trap."
Why Each Cycle Makes It Worse
The concern among researchers is not a single stop-start event. It is the compounding effect of multiple cycles. Each time you lose weight on a GLP-1, you lose a significant percentage of muscle. Each time you regain, you regain mostly fat. Over two or three cycles, the cumulative muscle loss can be substantial.
This matters because muscle is metabolically active tissue. It burns more calories at rest than fat does. Less muscle means a lower basal metabolic rate, which means your body needs fewer calories to maintain its weight. Paradoxically, each cycle of GLP-1 treatment can make it harder to maintain weight loss the next time — even with the medication.
No long-term research yet exists on health outcomes for people who have cycled through GLP-1 medications multiple times. This is a gap in the clinical literature that Dr. Almandoz and others have flagged as urgent. What we do know from decades of weight cycling research (the "yo-yo dieting" literature) is that repeated weight fluctuations are independently associated with higher cardiovascular risk, insulin resistance, and all-cause mortality.
Why People Stop (And Why It Matters for You)
The reasons patients discontinue GLP-1 therapy are overwhelmingly practical, not medical:
- Cost and insurance loss: With 24 million Americans losing GLP-1 coverage in the past year, cost is the single biggest driver of discontinuation. A patient paying $1,349 per month for Wegovy out of pocket often cannot sustain that indefinitely. Our [guide to losing GLP-1 coverage](/blog/insurance-dropped-glp1-coverage-options-2026) covers the options in detail.
- Supply disruptions: Although the semaglutide and tirzepatide shortages have largely resolved in 2026, localized supply gaps still occur and can force temporary discontinuation.
- Side effects: Nausea, vomiting, and gastrointestinal discomfort cause roughly 5 to 15 percent of patients to stop, most within the first two months.
- Perceived goal completion: Some patients stop when they hit their target weight, not realizing that the medication is managing an ongoing metabolic condition rather than providing a one-time fix.
How to Avoid the Cycling Trap
The clinical consensus is clear: if you start a GLP-1, the goal should be sustained therapy, not a course with an end date. Treating obesity with GLP-1 medication is more analogous to treating hypertension with blood pressure medication — you take it as long as you need it, which for most patients means indefinitely.
That leads to the practical question: how do you stay on therapy when the financial and logistical barriers are real?
1. Switch to an Affordable Provider — Don't Stop Cold
If cost is the reason you are considering stopping, switch to a lower-cost option before your current supply runs out. Compounded semaglutide through online telehealth programs starts at $99 per month — a fraction of the $1,349 Wegovy list price. These programs include the medication, prescribing physician, and ongoing medical support in a single monthly fee.
We independently reviewed 32 online GLP-1 providers and ranked them on price, safety, and medical oversight. The cheapest safe options start at $99 per month with no insurance required.
2. Add Resistance Training (Non-Negotiable)
This is the single most important countermeasure to GLP-1 muscle loss. Strength training two to three times per week can significantly reduce the proportion of lean mass lost during treatment. A 2025 study in The Lancet found that patients who combined GLP-1 therapy with structured resistance exercise preserved roughly 80 percent more muscle mass than those on medication alone.
You do not need a gym membership or a personal trainer. Bodyweight exercises — squats, push-ups, lunges, planks — performed consistently are sufficient. Our GLP-1 and exercise guide covers the specific protocols that clinical trials have validated.
3. Prioritize Protein Intake
Patients on GLP-1 medications often eat dramatically less, which means their protein intake drops proportionally. Inadequate protein accelerates muscle loss. The current clinical recommendation for patients on GLP-1 therapy is 1.0 to 1.2 grams of protein per kilogram of body weight per day — higher than the standard 0.8 grams recommended for the general population.
In practical terms, a 180-pound patient should aim for roughly 80 to 100 grams of protein daily. This often requires deliberate planning because the appetite suppression from the medication makes large meals difficult.
4. If You Must Stop, Taper Under Medical Supervision
Abrupt discontinuation causes the fastest rebound. If you need to stop — whether for cost, side effects, or another reason — work with your prescribing physician on a gradual dose reduction over four to eight weeks. This gives your appetite regulation system time to partially readjust rather than snapping back to pre-treatment hunger levels overnight.
The Bottom Line
The GLP-1 cycling trap is real, and it is driven primarily by cost and insurance barriers — not by patient choice. The patients who maintain the best long-term outcomes are those who find a way to sustain treatment continuously, even if that means switching from a brand-name drug to a more affordable compounded option.
If you are currently on a GLP-1 and worried about being able to continue, the worst thing you can do is wait until you run out. Start researching alternatives now. Our provider comparison tool ranks all 32 programs on price and medical quality. The match quiz can recommend a program based on your specific budget and insurance situation in 60 seconds.
Your muscles cannot tell the difference between quitting because you chose to and quitting because you could not afford it. The metabolic consequences are the same either way. The time to plan your continuation strategy is now — not after the prescription lapses.